Experimental obesity drug targets appetite through amylin, offering potential alternative to GLP-1 therapies

Medical Xpress - latest medical and health news stories ·
Health & Medicine United Kingdom

New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), and published in The Lancet Diabetes & Endocrinology shows that weekly injections of the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight—generally less weight loss than with existing…

Read original article on Medical Xpress - latest medical and health news stories →

Related news